<DOC>
	<DOCNO>NCT00788099</DOCNO>
	<brief_summary>Phase I Multicenter , Open-label , Clinical Pharmacokinetic Study Plitidepsin Combination Sorafenib Gemcitabine Patients Advanced Solid Tumors Lymphomas determine maximum tolerate dose ( MTD ) recommend dose ( RD ) plitidepsin combination sorafenib gemcitabine patient advance solid tumor lymphomas .</brief_summary>
	<brief_title>Study Plitidepsin Combination With Sorafenib Gemcitabine Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>Phase I Multicenter , Open-label , Clinical Pharmacokinetic Study Plitidepsin Combination Sorafenib Gemcitabine Patients Advanced Solid Tumors Lymphomas determine maximum tolerate dose ( MTD ) recommend dose ( RD ) , pharmacokinetics ( PK ) combination , drug-drug PK interaction , preliminary information clinical antitumor activity combination solid tumor , perform preliminary pharmacogenomic ( PGx ) study potential biomarkers sensitivity/resistance drug combination prognostic marker treatment outcome tumor tissue sample .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age ≥ 18 year ECOG performance status ( PS ) ≤ 1 Life expectancy ≥ 3 month Patients histologically/cytologically confirm diagnosis advance solid tumor lymphomas ( exclude Bcell derive lineage and/or primary cutaneous and/or leukemic disease ) refractory standard therapy reasonable chance benefit combination accord investigator 's opinion . Patients enter expansion cohort RD must : ) measurable disease accord RECIST , International Working Group Criteria ( IWC ) lymphoma patient b ) Evaluable disease serum marker case prostate ovarian cancer ( accord ProstateSpecific Antigen Working Group Recommendations ( PSAWGR ) Gynecologic Cancer Intergroup ( GCIG ) specific criterion , respectively At least 4 week since last chemotherapy ( 6 week since nitrosoureas mitomycin C ) , immunotherapy pharmacological treatment radiotherapy . In case hormonesensitive cancer progress hormone therapy ( i.e. , breast , prostate cancer ) , hormone therapy must either stop 4 week continue trial Adequate bone marrow , renal , hepatic , metabolic function ( assessed ≤ 7 day inclusion study ) : ) Platelet count ≥100 x109/L ( ≥ 75 x 109/L lymphoma patient ) , hemoglobin ≥9.0 g/dL ( ≥ 8.0 g/dL lymphoma patient ) absolute neutrophil count ( ANC ) ≥1.5 x109/L ( ≥1.0 x109/L lymphoma patient ) . b ) Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) : ≤ 3.0 x upper limit normal ( ULN ) , independently presence liver metastasis . c ) AP ≤2.5 x ULN ( ≤5 x ULN case extensive bone metastasis ) . ) Total bilirubin ≤1.5 x ULN ( unless due indirect hyperbilirubinemia gemcitabine combination arm ) . e ) Calculated CrCl : ≥ 40 mL/minute ( mean Crockroft Gault´s formula ) . f ) CPK ≤ 2.5 x ULN . g ) Albumin ≥2.5 g/dL . h ) Troponin I ≤ULN Recovery grade ≤1 AE derive previous treatment ( exclude alopecia grade peripheral neuropathy ≤ grade 2 ) LVEF ECHO MUGA low normal limit . Women childbearing potential must negative serum pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period 3 month discontinuation treatment . Acceptable method contraception include complete abstinence , intrauterine device ( IUD ) , oral contraceptive , subdermal implant double barrier Voluntarily sign date write informed consent prior specific study procedure . Previous treatment study drug ( expansion cohort RD ) . Concomitant diseases/conditions : History presence unstable angina , myocardial infarction , valvular heart disease congestive heart failure . Previous mediastinal radiotherapy . Previous treatment doxorubicin cumulative dos excess 450 mg/m2 Symptomatic arrhythmia arrhythmia require ongoing treatment , and/or prolong QTQTc &gt; grade 1 . Active uncontrolled infection . Myopathy clinical situation cause significant persistent elevation CPK ( &gt; 2.5 x ULN two different determination perform one week apart ) . Limitation patient 's ability comply treatment followup protocol . Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . Peripheral neuropathy &gt; grade 2 Symptomatic , progressive requiringcorticosteroids document brain metastasis leptomeningeal disease . Controlled stable brain metastasis without steroid allow Men woman childbearing potential use effective method contraception previously describe ; woman pregnant breast feed Patients radiation therapy great 35 % bone marrow History previous bone marrow and/or stem cell transplantation . ( Not patient treat RD expansion cohort ) High transfusional requirement ( &gt; 2 package red blood cell and/or 1 platelet transfusion ) 30 day prior inclusion study Participation another clinical trial concomitant treatment investigational product 30day period prior inclusion study . For sorafenib treatment : ) Hypersensitivity sorafenib component formulation . b ) Need chronic exposure antacid , H2 antagonists protonpump inhibitor . c ) Current need anticoagulation treatment ( include low dose warfarin LMWH treatment full anticoagulant dos ) . Abnormal thyroid function [ per normal serum thyroid stimulate hormone ( TSH ) within 14 day first dose study treatment ) . Uncontrolled arterial hypertension ( ≥160/100 ) despite optimal medical therapy . ChildPugh grade C hepatic cirrhosis cause For gemcitabine treatment : Hypersensitivity gemcitabine component formulation . Impending need palliative radiotherapy ameliorate painful metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Aplidin</keyword>
	<keyword>Plitidepsin</keyword>
	<keyword>Tumors</keyword>
	<keyword>Lymphomas</keyword>
</DOC>